Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
Brehanna Edwards, PGY-2 Health-System Pharmacy Administration and Leadership Resident at Ascension, shared on LinkedIn:
”Publication Alert
I’m excited to share that our latest work, “Rethinking lead-in strategies: evaluation of full vs. reduced dose factor Xa inhibitors in acute VTE,” has just been published in the Journal of Thrombosis and Thrombolysis.
This multicenter study across 29 hospitals examined whether patients with acute VTE who received prior therapeutic parenteral anticoagulation truly require a full lead-in period of apixaban or rivaroxaban.
Our findings suggest that a reduced lead-in strategy is not associated with increased risk of VTE recurrence or major bleeding, offering important real-world evidence to inform clinical decision-making.
Grateful for the collaborative effort behind this project and excited for the ongoing conversation about optimizing anticoagulation strategies in acute VTE care.”
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 31, 2026, 16:35IV Thrombolysis Does Not Improve Vision in Acute CRAO: Ahmed Koriesh on TenCRAOS Study
-
Jan 31, 2026, 16:24Joyce John Chalakkal: The Dangerous Area of The Face….
-
Jan 31, 2026, 16:04Rayya Saadiq Reflects On Qatar Health Congress 2026
-
Jan 31, 2026, 15:12Amar Raval on Oral Thin Film Drug Delivery Systems for Thrombosis Therapy
-
Jan 31, 2026, 14:40Heghine Khachatryan on WFH’s Call to Advance Health Equity for People with Bleeding Disorders
-
Jan 31, 2026, 14:10Emilia Arturo: Snake Venom, Clotting, and CryoEM!
-
Jan 31, 2026, 08:13Ming Y Lim On The Value of National Mentorship
-
Jan 31, 2026, 06:37Christian Schulze Presents The Post-Hoc Analysis of the DanGer Shock Trial
-
Jan 31, 2026, 06:27Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial